PMID- 32002765
OWN - NLM
STAT- MEDLINE
DCOM- 20201123
LR  - 20210402
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Print)
IS  - 0167-6806 (Linking)
VI  - 180
IP  - 2
DP  - 2020 Apr
TI  - Quantitative digital imaging analysis of HER2 immunohistochemistry predicts the 
      response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.
PG  - 321-329
LID - 10.1007/s10549-020-05546-0 [doi]
AB  - PURPOSE: Patients with HER2-positive breast cancer commonly receive anti-HER2 
      neoadjuvant chemotherapy and pathologic complete response (pCR) can be achieved 
      in up to half of the patients. HER2 protein expression detected by 
      immunohistochemistry (IHC) can be quantified using digital imaging analysis (DIA) 
      as a value of membranous connectivity. We aimed to investigate the association 
      HER2 IHC DIA quantitative results with response to anti-HER2 neoadjuvant 
      chemotherapy. METHODS: Digitized HER2 IHC whole slide images were analyzed using 
      Visiopharm HER2-CONNECT to obtain quantitative HER2 membranous connectivity from 
      a cohort of 153 HER2+ invasive breast carcinoma cases treated with anti-HER2 
      neoadjuvant chemotherapy (NAC). HER2 connectivity and other factors including 
      age, histologic grade, ER, PR, and HER2 fluorescence in situ hybridization (FISH) 
      were analyzed for association with the response to anti-HER2 NAC. RESULTS: 
      Eighty-three cases (54.2%) had pCR, while 70 (45.8%) showed residual tumor. 
      Younger age, negative ER/PR, higher HER2 DIA connectivity, higher HER2 FISH ratio 
      and copy number were significantly associated with pCR in univariate analysis. 
      Multivariate analysis demonstrated only age, HER2 DIA connectivity, PR 
      negativity, and HER2 copy number was significantly associated with pCR, whereas 
      HER2 DIA connectivity had the strongest association. CONCLUSIONS: HER2 IHC DIA 
      connectivity is the most important factor predicting pCR to anti-HER2 neoadjuvant 
      chemotherapy in patients with HER2-positive breast cancer.
FAU - Li, Aidan C
AU  - Li AC
AD  - Dublin Jerome High School, Dublin, OH, USA.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Zhao, Chao
AU  - Zhao C
AD  - Center for Biostatistics, Emory University, Atlanta, GA, USA.
FAU - Ma, Zhongliang
AU  - Ma Z
AD  - Department of Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 
      China.
FAU - Hartage, Ramon
AU  - Hartage R
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA.
FAU - Zhang, Yunxiang
AU  - Zhang Y
AD  - Department of Pathology, Weifang People's Hospital, Weifang, China.
FAU - Li, Xiaoxian
AU  - Li X
AUID- ORCID: 0000-0002-0995-1721
AD  - Department of Pathology, Emory University, Atlanta, GA, USA. xli40@emory.edu.
FAU - Parwani, Anil V
AU  - Parwani AV
AD  - Department of Pathology, The Ohio State University, Columbus, OH, USA. 
      Anil.Parwani@osumc.edu.
LA  - eng
GR  - P30 CA016058/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20200130
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*metabolism
MH  - Breast Neoplasms/drug therapy/metabolism/*pathology
MH  - Female
MH  - Humans
MH  - Image Processing, Computer-Assisted/*methods
MH  - Immunohistochemistry/*methods
MH  - Middle Aged
MH  - Neoadjuvant Therapy/*methods
MH  - Receptor, ErbB-2/antagonists & inhibitors/*metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Treatment Outcome
PMC - PMC8006811
MID - NIHMS1680480
OTO - NOTNLM
OT  - Anti-HER2 neoadjuvant chemotherapy
OT  - Breast carcinoma
OT  - HER2 immunohistochemistry
OT  - Pathologic complete response
OT  - Quantitative digital imaging analysis
COIS- Conflict of interest All authors have no financial relationship to disclose.
EDAT- 2020/02/01 06:00
MHDA- 2020/11/24 06:00
PMCR- 2021/04/01
CRDT- 2020/02/01 06:00
PHST- 2019/10/09 00:00 [received]
PHST- 2020/01/21 00:00 [accepted]
PHST- 2020/02/01 06:00 [pubmed]
PHST- 2020/11/24 06:00 [medline]
PHST- 2020/02/01 06:00 [entrez]
PHST- 2021/04/01 00:00 [pmc-release]
AID - 10.1007/s10549-020-05546-0 [pii]
AID - 10.1007/s10549-020-05546-0 [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2020 Apr;180(2):321-329. doi: 
      10.1007/s10549-020-05546-0. Epub 2020 Jan 30.